ATE324364T1 - Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalators - Google Patents
Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalatorsInfo
- Publication number
- ATE324364T1 ATE324364T1 AT03786896T AT03786896T ATE324364T1 AT E324364 T1 ATE324364 T1 AT E324364T1 AT 03786896 T AT03786896 T AT 03786896T AT 03786896 T AT03786896 T AT 03786896T AT E324364 T1 ATE324364 T1 AT E324364T1
- Authority
- AT
- Austria
- Prior art keywords
- tartrate
- production
- levalbuterol
- metered inhaler
- salt
- Prior art date
Links
- -1 L-TARTRATE LEVALBUTEROL SALT Chemical class 0.000 title 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 229950008204 levosalbutamol Drugs 0.000 abstract 1
- 229940071648 metered dose inhaler Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/30—Materials not provided for elsewhere for aerosols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0484—Alcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0488—Surfactant, e.g. for the lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43219502P | 2002-12-10 | 2002-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE324364T1 true ATE324364T1 (de) | 2006-05-15 |
Family
ID=32507867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03786896T ATE324364T1 (de) | 2002-12-10 | 2003-12-08 | Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalators |
| AT06110646T ATE498604T1 (de) | 2002-12-10 | 2003-12-08 | Aerosolformulierung umfassend levalbuterol l- tartratsalz |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06110646T ATE498604T1 (de) | 2002-12-10 | 2003-12-08 | Aerosolformulierung umfassend levalbuterol l- tartratsalz |
Country Status (19)
| Country | Link |
|---|---|
| US (8) | US7256310B2 (https=) |
| EP (3) | EP2292584B1 (https=) |
| JP (1) | JP4570960B2 (https=) |
| KR (3) | KR20100080865A (https=) |
| AT (2) | ATE324364T1 (https=) |
| AU (1) | AU2003295695B2 (https=) |
| CA (1) | CA2507572C (https=) |
| CY (2) | CY1106315T1 (https=) |
| DE (2) | DE60336089D1 (https=) |
| DK (3) | DK1671942T4 (https=) |
| ES (3) | ES2361172T5 (https=) |
| IL (2) | IL168739A (https=) |
| MX (1) | MXPA05006087A (https=) |
| NO (1) | NO331649B1 (https=) |
| NZ (1) | NZ541168A (https=) |
| PL (1) | PL212725B1 (https=) |
| PT (3) | PT1572622E (https=) |
| SI (2) | SI1671942T2 (https=) |
| WO (1) | WO2004052835A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6466862B1 (en) * | 1999-04-19 | 2002-10-15 | Bruce DeKock | System for providing traffic information |
| EA200700600A1 (ru) * | 2004-09-09 | 2008-02-28 | Сипла Лимитед | Фармацевтическая композиция, содержащая изомер бета-миметического агента и антихолинергический агент |
| CA2591406A1 (en) * | 2004-12-17 | 2006-06-22 | Cipla Limited | Pharmaceutical compounds and compositions |
| RU2440972C2 (ru) | 2004-12-17 | 2012-01-27 | Сипла Лимитед | Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его |
| US8751589B2 (en) | 2011-04-13 | 2014-06-10 | Jingle Technologies Llc | Systems and methods for transmitting information, alerts, and/or comments to participants based on location information |
| EP3042892A1 (en) | 2015-01-09 | 2016-07-13 | Deva Holding Anonim Sirketi | Amorphisation of levosalbutamol tartrate |
| CN106727318A (zh) * | 2016-12-22 | 2017-05-31 | 山东京卫制药有限公司 | 一种气雾剂及其制备方法 |
| US20210290568A1 (en) * | 2020-03-19 | 2021-09-23 | Cai Gu Huang | Inhalable formulation of a solution containing levalbuterol tartrate |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
| US5776434A (en) | 1988-12-06 | 1998-07-07 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| GB8828477D0 (en) † | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5345980A (en) | 1989-09-21 | 1994-09-13 | Glaxo Group Limited | Method and apparatus an aerosol container |
| US5362755A (en) | 1990-01-05 | 1994-11-08 | Sepracor, Inc. | Method for treating asthma using optically pure (R)-albuterol |
| US5255183A (en) * | 1990-05-29 | 1993-10-19 | Interactive Voice Data System Inc. | Telephone-based personnel tracking system |
| HUT67445A (en) * | 1991-06-10 | 1995-04-28 | Schering Corp | Aerosol formulations containing 1,1,1,2-tetrafluorethane |
| EP0617610B1 (en) | 1991-12-18 | 1997-03-19 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| US5399765A (en) * | 1994-05-23 | 1995-03-21 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
| US5545745A (en) | 1994-05-23 | 1996-08-13 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
| AP791A (en) * | 1995-04-14 | 1999-12-17 | Glaxo Wellcome Inc | Metered dose inhaler for albuterol. |
| US5603918A (en) | 1995-06-09 | 1997-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aerosol composition of a salt of ipratropium and a salt of albuterol |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| GB9806462D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Improved compositions for inhalation |
| JP4570251B2 (ja) * | 1998-07-24 | 2010-10-27 | ヤゴテック アーゲー | 医薬用エーロゾル製剤 |
| CN1150890C (zh) * | 1998-08-04 | 2004-05-26 | 杰格研究股份公司 | 药用气溶胶制剂 |
| AU756852B2 (en) * | 1998-11-13 | 2003-01-23 | Jagotec Ag | Dry powder for inhalation |
| CN1173929C (zh) | 1999-10-19 | 2004-11-03 | 中国科学院成都有机化学研究所 | 光学纯肾上腺素类β-激动剂的组合拆分制备法 |
| US6451289B2 (en) | 2000-03-24 | 2002-09-17 | Sepracor Inc. | Albuterol formulations |
| GB0030171D0 (en) | 2000-12-11 | 2001-01-24 | Cipla Ltd | Process for preparing isomers of salbutamol |
| NZ528640A (en) * | 2001-03-30 | 2004-06-25 | Jagotec Ag | Medical aerosol formulations |
| CN1206205C (zh) * | 2001-04-26 | 2005-06-15 | 中国科学院成都有机化学研究所 | R－沙丁胺醇酒石酸盐的制备方法 |
| DE10120531A1 (de) * | 2001-04-26 | 2002-10-31 | Basf Ag | Neue Reaktivfarbstoffe und deren Verwendung zum Färben von Substraten, welche nucleophile Gruppen enthalten |
-
2003
- 2003-12-08 DE DE60336089T patent/DE60336089D1/de not_active Expired - Lifetime
- 2003-12-08 ES ES06110646.4T patent/ES2361172T5/es not_active Expired - Lifetime
- 2003-12-08 AT AT03786896T patent/ATE324364T1/de active
- 2003-12-08 EP EP10176026.2A patent/EP2292584B1/en not_active Expired - Lifetime
- 2003-12-08 PT PT03786896T patent/PT1572622E/pt unknown
- 2003-12-08 KR KR1020107014278A patent/KR20100080865A/ko not_active Ceased
- 2003-12-08 DK DK06110646.4T patent/DK1671942T4/da active
- 2003-12-08 DE DE60304900T patent/DE60304900T2/de not_active Expired - Lifetime
- 2003-12-08 JP JP2004559144A patent/JP4570960B2/ja not_active Expired - Fee Related
- 2003-12-08 US US10/728,873 patent/US7256310B2/en not_active Expired - Lifetime
- 2003-12-08 DK DK03786896T patent/DK1572622T3/da active
- 2003-12-08 WO PCT/US2003/037079 patent/WO2004052835A1/en not_active Ceased
- 2003-12-08 AU AU2003295695A patent/AU2003295695B2/en not_active Expired
- 2003-12-08 ES ES03786896T patent/ES2263051T3/es not_active Expired - Lifetime
- 2003-12-08 SI SI200331954T patent/SI1671942T2/sl unknown
- 2003-12-08 EP EP06110646.4A patent/EP1671942B2/en not_active Expired - Lifetime
- 2003-12-08 MX MXPA05006087A patent/MXPA05006087A/es active IP Right Grant
- 2003-12-08 SI SI200330331T patent/SI1572622T1/sl unknown
- 2003-12-08 PT PT101760262T patent/PT2292584T/pt unknown
- 2003-12-08 AT AT06110646T patent/ATE498604T1/de active
- 2003-12-08 CA CA2507572A patent/CA2507572C/en not_active Expired - Lifetime
- 2003-12-08 KR KR1020057010435A patent/KR20050088307A/ko not_active Ceased
- 2003-12-08 PL PL377336A patent/PL212725B1/pl unknown
- 2003-12-08 DK DK10176026.2T patent/DK2292584T3/en active
- 2003-12-08 EP EP03786896A patent/EP1572622B1/en not_active Expired - Lifetime
- 2003-12-08 ES ES10176026.2T patent/ES2626648T3/es not_active Expired - Lifetime
- 2003-12-08 NZ NZ541168A patent/NZ541168A/en not_active IP Right Cessation
- 2003-12-08 KR KR1020087028024A patent/KR101166955B1/ko not_active Expired - Fee Related
- 2003-12-08 PT PT06110646T patent/PT1671942E/pt unknown
-
2005
- 2005-05-23 IL IL168739A patent/IL168739A/en active IP Right Grant
- 2005-07-08 NO NO20053339A patent/NO331649B1/no not_active IP Right Cessation
-
2006
- 2006-07-03 CY CY20061100912T patent/CY1106315T1/el unknown
-
2007
- 2007-08-08 US US11/891,048 patent/US20080119564A1/en not_active Abandoned
-
2010
- 2010-07-09 US US12/833,882 patent/US20100272654A1/en not_active Abandoned
-
2011
- 2011-03-11 CY CY20111100273T patent/CY1111330T1/el unknown
- 2011-04-14 IL IL212369A patent/IL212369A/en active IP Right Grant
-
2012
- 2012-10-02 US US13/633,801 patent/US20130028845A1/en not_active Abandoned
-
2013
- 2013-04-29 US US13/873,084 patent/US8765153B2/en not_active Expired - Lifetime
-
2014
- 2014-05-21 US US14/283,754 patent/US20150071969A1/en not_active Abandoned
-
2016
- 2016-01-22 US US15/003,883 patent/US20160368858A1/en not_active Abandoned
-
2017
- 2017-10-18 US US15/786,917 patent/US20180222845A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE502006002956D1 (de) | Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung | |
| TW200612910A (en) | Medicaments comprising carbonyl compounds, and the use thereof | |
| CY1115180T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
| DE602004029580D1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| UA102236C2 (uk) | Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування | |
| NO20085066L (no) | 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| TW200738242A (en) | Dihydropteridinones in the treatment of respiratory diseases | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| CY1117603T1 (el) | Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2 | |
| DE602005004808D1 (de) | Körperpflegezusammensetzungen mit salzen von mit dihydroxypropyltri(c1-c3alkyl) ammonium monosubstituierten polyolen | |
| DE112007001669A5 (de) | Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung | |
| MX2007008928A (es) | Aminoacidos n-halogenados y aminoacidos n, n-dihalogenados en combinacion con acidos hipohalosos. | |
| TW200732303A (en) | Novel fused pyrrole derivatives | |
| UA85707C2 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
| ATE324364T1 (de) | Verwendung vom l-tartrat levalbuterolsalz in der herstellung eines dosierinhalators | |
| IL185410A0 (en) | Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease | |
| WO2007020261A3 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
| ATE424195T1 (de) | Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen | |
| WO2009057528A1 (ja) | 創薬のためのｐｅｔスクリーニング用分子プローブを製造するためのキット | |
| DE602005000442D1 (de) | Verwendung von alpha-1-Antitrypsin zur Herstellung eines Medikaments zur Behandlung von Fibromyalgie | |
| ATE491443T1 (de) | Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen | |
| ATE523201T1 (de) | Verwendung von salzsäure bei der herstellung eines medikaments zur behandlung von diabetes | |
| RU2006110457A (ru) | Средство для лечения сахарного диабета | |
| ZA200711062B (en) | Thiazolopyrimidines for use in therapy | |
| GEP20105034B (en) | 1,2,4,5-tetrahydro-3h-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1572622 Country of ref document: EP |